docetaxel anhydrous has been researched along with cabazitaxel in 238 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (cabazitaxel) | Trials (cabazitaxel) | Recent Studies (post-2010) (cabazitaxel) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 601 | 79 | 563 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 187 (78.57) | 24.3611 |
| 2020's | 51 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Talele, TT | 1 |
| Ding, N; Guo, J; Li, Y; Ren, S; Wang, J; Wang, Y; Zhang, M | 1 |
| Ensley, JF; Folbe, AJ; Kafri, Z; Kim, H; Lin, HS; Lonardo, F; Stevens, T; Won, J; Yoo, GH | 1 |
| Dorff, TB; Quinn, DI | 1 |
| Bodrogi, I; de Bono, JS; Gravis, G; Gupta, S; Hansen, S; Kocak, I; Machiels, JP; Mackenzie, MJ; Oudard, S; Ozguroglu, M; Roessner, M; Sartor, AO; Shen, L | 1 |
| Pal, SK; Sartor, O | 1 |
| Figg, WD | 1 |
| Bilusic, M; Dahut, WL | 1 |
| Pal, SK; Sartor, O; Twardowski, P | 1 |
| Halstead, M; Katz, L; Sartor, O | 1 |
| Goetz, D | 1 |
| Alhasso, A; Ansari, A; Ansari, J; Glaholm, J; Hussain, SA; Mahmood, R | 1 |
| Miller, K | 1 |
| Petrylak, DP | 3 |
| Guancial, EA; Taplin, ME | 1 |
| Gelpi, F; Gomella, LG; Kelly, WK | 1 |
| Higano, CS | 1 |
| de Bono, JS; Massard, C; Michels, RM; Sartor, O | 1 |
| Börgermann, C; Molitor, B | 1 |
| Bahl, A; Bellmunt, J; Oudard, S | 1 |
| Gschwend, JE; Heck, MM; Höppner, M; Horn, T; Retz, M; Thalgott, M | 1 |
| Perry, CJ; Sundar, S | 1 |
| Beuzeboc, P; Goldwasser, F; Ropert, S; Zerbib, M | 1 |
| Gross-Goupil, M; Pasticier, G; Ravaud, A; Roca, S | 1 |
| Herchenhorn, D; Maluf, FC; Smaletz, O | 1 |
| Bahl, A; Masson, S | 1 |
| Gottfried, M; Keizman, D; Maimon, N | 1 |
| Alesini, D; Altavilla, A; Campennì, GM; Cortesi, E; Iacovelli, R; Palazzo, A; Procopio, G; Risi, E | 1 |
| Adler, AI; George, E; Jilani, A | 1 |
| Joly, F; Lheureux, S | 1 |
| Deep, A; Dhingra, R; Malhotra, M; Narasimhan, B; Phogat, P; Sharma, PC; Sharma, T | 1 |
| Heidenreich, A; Pfister, D | 1 |
| Albiges, L; Escudier, B; Fizazi, K; Loriot, Y; Massard, C | 1 |
| Aapro, MS | 1 |
| Clarke, NW | 1 |
| Penson, DF; Resnick, MJ | 1 |
| Antonarakis, ES; Eisenberger, MA | 1 |
| Lewis, B; Pal, SK; Sartor, O | 1 |
| Albers, P; Arsov, C; Bokemeyer, C; Ecstein-Fraisse, E; Gschwend, J; Heidenreich, A; Heinrich, E; Honecker, F; Keck, B; Miller, K; Müller, SC; Otremba, B; Pfister, D; Retz, M; Rogenhofer, S; Scholz, HJ; Steiner, U; Trojan, L; Volkmer, B; Wirth, M | 1 |
| Caffo, O; Galligioni, E; Russo, L; Veccia, A | 1 |
| Birtle, A | 1 |
| Bijnsdorp, IV; Geldof, AA; Hoekstra, OS; Oprea-Lager, DE; VAN DEN Eertwegh, AJ; VAN Moorselaar, RJ | 1 |
| Lorch, A | 1 |
| Beijnen, JH; Cirkel, GA; Hillebrand, MJ; Kort, A; Rosing, H; Schellens, JH; Schinkel, AH; Voest, EE | 1 |
| Hotte, SJ; Loblaw, DA; Walker-Dilks, C; Winquist, E | 1 |
| Bissery, MC; Bouchard, H; Calvet, L; Combeau, C; Commerçon, A; Lavelle, F; Lejeune, P; Riou, JF; Sémiond, D; Vrignaud, P | 1 |
| Bellmunt, J; Fitzpatrick, JM; Jenkins, C; Merseburger, AS; Parker, C | 1 |
| Bahl, A; de Bono, JS; Devin, J; Gravis, G; Hansen, S; Kocak, I; Oudard, S; Ozgüroglu, M; Sartor, AO; Shen, L; Tombal, B | 1 |
| Batty, N; Pili, R; Yarlagadda, N | 1 |
| Armstrong, AJ; de Bono, J; Halabi, S; Kaplan, EB; Lin, CY; Oudard, S; Petrylak, D; Sartor, O; Shen, L; Small, EJ; Sternberg, CN | 1 |
| Bastide, C; Beuzeboc, P; Brenot-Rossi, I; Bruyère, F; Guy, L; Karsenty, G; Mongiat-Artus, P | 1 |
| de Morrée, ES; de Wit, R; Mathijssen, RH; Moll, JM; Teubel, W; van Royen, ME; van Soest, RJ; van Weerden, WM; Wiemer, EA | 1 |
| Afonso, J; Antón Aparicio, LM; Campos, B; Fernández, O; Lázaro, M; León, L; Vázquez, S | 1 |
| Borre, M; Brasso, K; Iversen, P; Rathenborg, P; Røder, MA; Thomsen, FB | 1 |
| Ansari, J; Bahl, A; Birtle, A; Butt, M; Chowdhury, S; Eswar, CV; Hughes, S; Malik, Z; Payne, H; Sundar, S | 1 |
| D'Amico, AV | 1 |
| Aragon-Ching, JB; El-Bahesh, E; Elkon, J; Gupta, K | 1 |
| Altavilla, A; Attard, G; Bianchini, D; de Bono, JS; Dearnaley, D; Ferraldeschi, R; Lorente, D; Omlin, AG; Parker, C; Pezaro, CJ | 1 |
| Bahl, A | 1 |
| Buzaid, AC; Sartor, O; Schutz, FA | 1 |
| Muggia, FM | 1 |
| Gurney, H; Parente, P; Parnis, F | 1 |
| de Bruijn, P; Ghobadi Moghaddam-Helmantel, IM; Gibson, AA; Gui, C; Hagenbuch, B; Hu, S; Mathijssen, RH; Nieuweboer, AJ; Sparreboom, A | 1 |
| Albers, P; Eichenauer, R; Geiges, G; Grimm, MO; König, F; Mickisch, G; Miller, K; Pfister, D; Schwentner, C; Suttmann, H; Zastrow, S | 1 |
| Al Nakouzi, N; Albigès, L; Beuzeboc, P; de La Motte Rouge, T; Fizazi, K; Gajda, D; Gleave, M; Gross-Goupil, M; Guillot, A; Le Moulec, S; Loriot, Y; Massard, C; Wang, C | 1 |
| Tombal, B | 1 |
| Azarenko, O; Jordan, MA; Mah, J; Smiyun, G; Wilson, L | 1 |
| Antón Aparicio, LM; Batista, N; Castellano, D; Esteban, E; Germà, JR; Luque, R; Maroto, P; Méndez-Vidal, MJ; Pérez-Valderrama, B; Sánchez-Hernández, A | 1 |
| Berger, R; Frank, SJ; Gez, E; Hanovich, E; Hayat, H; Keizman, D; Kovel, S; Neiman, V; Peer, A; Rosenbaum, E; Sella, A; Sella, T; Sharide, D | 1 |
| Bobilev, D; Ditzler, S; Eslamy, H; Girard, E; Lee, D; Olson, J; Park, J; Richards, A; Vrignaud, P; Yagle, K | 1 |
| Basch, E; Bennett, CL; Carducci, M; Chen, RC; Dusetzina, SB; Frame, JN; Garrels, K; Hotte, S; Kattan, MW; Loblaw, DA; Oliver, TK; Raghavan, D; Rumble, RB; Saad, F; Taplin, ME; Virgo, KS; Walker-Dilks, C; Williams, J; Winquist, E; Wootton, T | 1 |
| Bergman, AM; Bos, MM; Coenen, JL; de Wit, R; Gelderblom, H; Hamberg, P; Lolkema, MP; Los, M; Ten Tije, AJ; van den Berg, P; van den Eertwegh, AJ; van Oort, IM; Westgeest, HM; Wissing, MD | 1 |
| Joerger, M | 2 |
| Bijnsdorp, IV; Geldof, AA; Hoekstra, OS; Oprea-Lager, DE; van de Ven, PM; van den Eertwegh, AJ; van Kanten, MP; van Moorselaar, RJ | 1 |
| Beltran, H; Cheung, C; Fontugne, J; Galletti, G; Giannakakou, P; Horvath, LG; Kench, JG; Kimovski, D; MacDonald, TY; Matov, A; Miguel Mosquera, J; Nanus, DM; O'Toole, S; Rickman, DS; Rubin, MA; Suk Chae, S; Sung, M; Tagawa, ST | 1 |
| Aieta, M; Alesini, D; Basso, U; Burgio, SL; Buttigliero, C; Caffo, O; Campadelli, E; Carrozza, F; Conteduca, V; Cortesi, E; D'Angelo, A; D'Aniello, C; De Giorgi, U; Donini, M; Facchini, G; Fornarini, G; Fratino, L; Galligioni, E; Gasparro, D; La Torre, L; Lo Re, G; Macrini, S; Maines, F; Massari, F; Messina, C; Morelli, F; Mucciarini, C; Ortega, C; Procopio, G; Ricotta, R; Ruatta, F; Sabbatini, R; Santarossa, S; Santini, D; Sartori, D; Sava, T; Tarasconi, S; Tucci, M; Veccia, A; Verderame, F; Vicario, G; Zagonel, V; Zucali, P; Zustovich, F | 1 |
| de Morrée, ES; de Ridder, CMA; de Wit, R; Kweldam, CF; Mathijssen, RHJ; van Soest, RJ; van Weerden, WM; Wiemer, EAC | 1 |
| Burchardt, M; Fussek, S; Knabbe, C; Oswald, S; Preuß, M; Rauschenberger, L; Saupe, M; Stope, MB; Walther, R; Zimmermann, U | 1 |
| Berman-Booty, LD; Ciment, SJ; de Leeuw, R; Den, RB; Dicker, AP; Gomella, LG; Kelly, WK; Knudsen, KE; Lallas, CD; Schiewer, MJ; Trabulsi, EJ | 1 |
| Cathomas, R; De Bono, JS; Gillessen, S; Omlin, A; Rothermundt, C; Sartor, O; Shen, L; Su, Z | 1 |
| Bhor, M; Bhowmik, D; Hennessy, D; Nicacio, L; Rembert, D; Schnadig, I; Shen, L; Sonpavde, G; Yap, M | 1 |
| Ndibe, C; Sonpavde, G; Wang, CG | 1 |
| Arai, Y; Furuse, H; Ide, H; Kakehi, Y; Kamba, T; Kato, M; Kimura, T; Kitamura, H; Kosaka, T; Kume, H; Miyazaki, J; Mukai, H; Nakai, Y; Nozawa, M; Ohno, K; Okihara, K; Onozawa, Y; Suzuki, K; Takahashi, S; Tomita, Y; Uemura, H; Yokomizo, A | 1 |
| Azimi, A; Baltatzis, G; Chioureas, D; Fonseca, P; Hultenby, K; Kharaziha, P; Lennartsson, L; Nilsson, S; Panaretakis, T; Rutishauser, D; Ullén, A; Yachnin, J; Zubarev, R | 1 |
| Deguchi, T; Ehara, H; Fujita, Y; Ito, H; Ito, M; Kameyama, K; Kanimoto, Y; Kato, T; Kawakami, K; Mizutani, K; Nakane, K; Seishima, M | 1 |
| Beuzeboc, P; Massard, C | 1 |
| Churchill, CD; Klobukowski, M; Tuszynski, JA | 1 |
| Bianco, V; Fiaschi, AI; Francini, E; Laera, L; Petrioli, R; Ponchietti, R; Roviello, G | 1 |
| Attard, G; de Bono, JS; Lorente, D; Mateo, J; Perez-Lopez, R | 1 |
| Fiaschi, AI; Francini, E; Laera, L; Petrioli, R; Ponchietti, R; Roviello, G | 1 |
| Kyprianou, N; Martin, SK | 1 |
| Antonarakis, ES; Carducci, MA; Chen, Y; Eisenberger, MA; Lu, C; Luo, J; Nakazawa, M; Paller, CJ | 1 |
| Gorlick, R; Houghton, PJ; Kang, MH; Kolb, EA; Kurmasheva, RT; Maris, JM; Reynolds, CP; Smith, MA; Wu, J | 1 |
| Alvarez, X; Dong, Y; Fu, X; Ledet, E; Li, J; Liu, X; Qi, Y; Sartor, O; Zhang, G; Zhang, H | 1 |
| Antonarakis, ES; Carducci, MA; Chen, Y; Denmeade, SR; Eisenberger, MA; Lu, C; Luber, B; Luo, J; Nadal, R; Nakazawa, M; Paller, CJ; Wang, H | 1 |
| Crawford, ED; Higano, CS; Hussain, M; Petrylak, DP; Shore, ND | 1 |
| Bergman, AM; Bos, MM; Chitu, D; de Morrée, ES; de Wit, R; Goey, SH; Hamberg, P; Mathijssen, RH; Nieuweboer, AJ; van der Meer, N; van Soest, RJ | 1 |
| Bria, E; Caffo, O; Galligioni, E; Maines, F; Tortora, G; Trentin, C; Veccia, A | 1 |
| Audenet, F; Basset, V; Branchereau, J; de La Taille, A; Flamand, V; Lebdai, S; Lebret, T; Murez, T; Neuzillet, Y; Ploussard, G | 1 |
| Ohlmann, CH | 1 |
| Antonarakis, ES; Maughan, BL | 1 |
| Lee, S; Lichtenthal, B; Ojima, I; Wang, C; Wang, X | 1 |
| Claros, M; Nathanson, L; Ramachandran, K; Singal, R; Speer, C | 1 |
| Collard, O; De Laroche, G; Falk, AT; Fournel, P; Guillot, A; Magné, N; Merrouche, Y; Méry, B; Moriceau, G; Pacaut, C; Trone, JC | 1 |
| Uemura, H | 1 |
| de Bono, J; de Wit, R; Liewen, H; Meisel, A; Sartor, O; Stenner-Liewen, F; Vogt, DR; von Felten, S | 1 |
| Chen, XX; Gao, F; Qu, XX; Tian, XC; Wang, D; Wen, G; Zhou, XL | 1 |
| Bertaglia, V; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
| Carrera, G; Fernández, P; Gaba, L; García-Recio, S; Jiménez, N; Marín-Aguilera, M; Mellado, B; Paré, L; Pereira, MV; Prat, A; Reig, Ò | 1 |
| Aghai, A; Burger, H; de Bruijn, P; de Morrée, E; de Ridder, C; de Wit, R; Ghobadi Moghaddam-Helmantel, I; Mathijssen, R; van Soest, R; van Weerden, W; Wiemer, E | 1 |
| Ackermann, CJ; Gillessen, S; Hager, S; Joerger, M; Omlin, A | 1 |
| Bisbjerg, R; Daugaard, G; Kongsted, P; Lindberg, H; Sengeløv, L; Svane, IM | 1 |
| Adler, AI; Goodall, M; Kelly, V; Lovett, R | 1 |
| Arslan, C | 1 |
| Aghai, A; Böttcher, R; Burger, H; de Morrée, ES; de Ridder, CM; de Wit, R; Gibson, AA; Mathijssen, RH; Sparreboom, A; van Soest, RJ; van Weerden, WM; Wiemer, EA | 1 |
| Aarts, MJ; Badrising, SK; Bergman, AM; Coenen, JL; de Jong, IJ; Gelderblom, H; Haanen, JB; Hamberg, P; Kerver, ED; Los, M; van den Berg, HP; van den Eertwegh, AJ; van der Noort, V; van Oort, IM; van Voorthuizen, T; Vrijaldenhoven, S | 1 |
| Penel, N | 1 |
| Dermitzaki, EK; Georgoulias, V; Hatzidaki, D; Karavassilis, V; Katsaounis, P; Kentepozidis, N; Koinis, F; Kotsakis, A; Matikas, A; Mavroudis, D; Samantas, E; Varthalitis, II | 1 |
| Duensing, S; Heller, M; Hohenfellner, M; Li, J; Mang, J; Merkle, K; Schüler, J; Tolstov, Y | 1 |
| Bolton, D; Corfield, J; Crozier, J; Joshua, AM; Lawrentschuk, N | 1 |
| Carducci, MA; Markowski, MC | 1 |
| Cicero, G; De Luca, R; Dieli, F; Dispensa, N; Dorangricchia, P; Galvano, A; Lo Re, G; Serretta, V | 1 |
| Albiges, L; Attard, G; Bianchini, D; de Bono, J; Fizazi, K; Loriot, Y; Massard, C; Mateo, J; Mehra, N; Petrylak, DP; Pezaro, C; Ryan, CJ; Shen, L; Varga, A | 1 |
| Bloemendal, HJ; de Klerk, JM; Geldof, AA; Hendrikse, NH; Lange, R; Paap, M; ter Heine, R; Tromp, AM; van Wieringen, WN | 1 |
| Bloemendal, HJ; Bouman-Wammes, EW; de Klerk, JMH; van den Eertwegh, AJM; van Dodewaard-de Jong, JM; Verheul, HMW | 1 |
| Corman, S; Drea, E; Flannery, K; Gao, X; Hudspeth, L; Miao, R; Xue, M | 1 |
| Arranz, JA; Climent, MÁ; Gironés, R; Torregrosa, MD; Vázquez, S | 1 |
| Breaker, K; Flaig, TW; Gao, D; Kessler, ER; Lam, ET; Wacker, M; Wold, M | 1 |
| Armstrong, CM; Evans, CP; Gao, AC; Liu, C; Lombard, AP; Lou, W | 1 |
| Azarenko, O; Jordan, MA; LaPointe, NE; Miller, H; Rifkind, A; Smiyun, G; Wilson, L | 1 |
| Izumi, K; Kadono, Y; Kitagawa, Y; Konaka, H; Mizokami, A | 1 |
| Gallagher, M; Reinhart, M; Sartor, O; Summers, N; Vanderpuye-Orgle, J | 1 |
| Hinz, S | 1 |
| Albany, C; Antonarakis, ES; Bai, Y; Ballman, K; Eisenberger, MA; Galletti, G; Giannakakou, P; Gjyrezi, A; Gruber, CN; Kirby, BJ; Lannin, TB; Nanus, DM; North, S; Portella, L; Pratt, ED; Saad, F; Sonpavde, G; Stewart, J; Suri, S; Szatrowski, T; Tagawa, ST; Tasaki, S; Tsao, CK; Vanhuyse, M; Worroll, D; Zaher, A; Zhou, W | 1 |
| Crumbaker, M; Gurney, H | 1 |
| Albers, P; Goebell, PJ; Grimm, MO; Klier, J; König, F; Machtens, S; Ohlmann, CH; Schostak, M; Schrader, AJ | 1 |
| Armstrong, CM; Cucchiara, V; Evans, CP; Gao, AC; Gu, X; Liu, C; Lombard, AP; Lou, W | 1 |
| Aki, R; Ito, T; Matsushita, Y; Miyake, H; Motoyama, D; Otsuka, A; Sugiyama, T; Tamura, K | 1 |
| Bianchini, D; de Bono, J; Gilman, A; Hall, E; IJzerman, M; Kolinsky, M; Lorente, D; Mateo, J; Mehra, N; Miranda, M; Omlin, A; Payne, H; Perez, R; Pezaro, C; Porta, N; Ravi, P; Rescigno, P; Terstappen, L; Tunariu, N | 1 |
| Cheng, WY; Dhawan, R; Duh, MS; Gauthier-Loiselle, M; Miao, R; Oh, WK; Sung, J; Vekeman, F | 1 |
| Armstrong, AJ; Zhang, T | 1 |
| Beer, TM | 1 |
| Bando, Y; Fujisawa, M; Furukawa, J; Harada, KI; Hinata, N; Nakano, Y; Terakawa, T | 1 |
| Bteich, J; Ernsting, MJ; Hoang, B; Kiyota, T; Li, SD; Tang, WS; Undzys, E | 1 |
| Alekseev, B; Beer, TM; Blumenstein, B; Chi, KN; Fizazi, K; Fléchon, A; Gravis, G; Hotte, SJ; Jacobs, CA; Joly, F; Malik, Z; Matveev, V; Saad, F; Stewart, PS | 1 |
| Albers, P; Bögemann, M; Goebell, P; Gschwend, JE; Heidenreich, A; Klier, J; König, F; Machtens, S; Pantel, K; Thomas, C | 1 |
| Bansal, S; Emmenegger, U; Kulkarni, GS; Nam, RK; Saskin, R; Satkunasivam, R; Wallis, CJD | 1 |
| Boér, K; Dank, M; Dankovics, Z; Küronya, Z; Lahm, E; Maráz, A; Petrányi, Á; Révész, J; Ruzsa, Á; Szûcs, M; Valikovics, A; Vas, M | 1 |
| Heidenreich, A; Nilsson, S; Parker, C; Shore, N | 1 |
| Angelergues, A; Balea, BC; Bellmunt, J; Birtle, AJ; Borrega, P; Carbonero, IG; Castellano, DE; Delanoy, N; Efstathiou, E; Esteban, E; Flechon, A; Gonzalez, I; Guillot, A; Gyftaki, R; Lainez, N; Le Moulec, S; Munarriz, J; Oudard, S; Ozguroglu, M; Rubio, G; Wysocki, PJ | 1 |
| Alexander, DD; Deuson, R; Fryzek, JP; Reichert, H; Summers, N; Townes, L; Vanderpuye-Orgle, J | 1 |
| Taneja, SS | 1 |
| Filleur, S; Jarvis, C; Martinez-Marin, D; Nelius, T; Sennoune, SR | 1 |
| Boyer, Z; Castillo, L; Chan, CL; Daly, RJ; Deng, N; Dodson, E; Elsworth, B; Horvath, LG; Lee, BY; Lin, HM; Nikolic, I; Simpson, KJ; Spielman, C; Swarbrick, A; Yang, J; Yeung, NK | 1 |
| Barata, P; Emamekhoo, H; Garcia, JA; Gilligan, T; Koshkin, V; Kyriakopoulos, C; Mendiratta, P; Ornstein, M; Rini, BI; Tyler, A | 1 |
| Christensen, M; Doughty, H; Kenealey, J; Lawson, J; Oblad, R | 1 |
| Armstrong, CM; Cucchiara, V; Evans, CP; Gao, AC; Liu, C; Liu, L; Lombard, AP; Lou, W; Yang, JC; Zhao, R | 1 |
| Huang, C; Song, P; Wang, Y | 1 |
| Auduteau, L; Boughanem, C; Caudron, E; Jaccoulet, E; Prognon, P | 1 |
| Barnes, G; Bury, D; Carles, J; El Karak, F; Ghosn, M; Hitier, S; Katolicka, J; Koroleva, I; Korunkova, H; Makdessi, J; Özatilgan, A; Pichler, A; Tomova, A | 1 |
| Atzrodt, J; Burhop, A; Derdau, V; Jones, S; Weck, R | 1 |
| Baldauf, S; Bartsch, G; Borgmann, H; Brandt, MP; Dotzauer, R; Frees, S; Haferkamp, A; Jäger, W; Neisius, A; Schneider, M; Thomas, C; Tsaur, I | 1 |
| Cheng, WY; Drea, E; Duh, MS; Gauthier-Loiselle, M; Miao, R; Oh, WK; Szatrowski, TP; Vekeman, F | 1 |
| Hofer, MD | 1 |
| Bolognini, C; Gassian, N; Klajer, E; Loriot, Y; Meynard, G; Thiery-Vuillemin, A | 1 |
| Hongo, H; Kikuchi, E; Kosaka, T; Mizuno, R; Oya, M; Watanabe, K | 1 |
| Ballester, I; González-Billalabeitia, E; Rosino, A; Tudela, J | 1 |
| Bosland, MC; Eskra, JN; Schlicht, MJ | 1 |
| Jaal, J; Kase, M; Lust, H; Saar, M; Sak, K | 1 |
| Eto, M; Imada, K; Inokuchi, J; Kashiwagi, E; Murakami, T; Shiota, M; Takeuchi, A; Tatsugami, K | 1 |
| Buonerba, C; Di Lorenzo, G; Fizazi, K; Pagliuca, M | 1 |
| Feng, FY; Fizazi, K; Vicier, C | 1 |
| Eto, M; Harano, M; Hasegawa, S; Kuroiwa, K; Nakamura, M; Sakamoto, N; Seki, N; Shiota, M; Tomoda, T; Yokomizo, A; Yunoki, T | 3 |
| Åslund, AKO; Bjerkvig, R; Borgos, SE; Davies, CL; Miletic, H; Mørch, Y; Snipstad, S; Sulheim, E | 1 |
| Alexandre, J; Baciarello, G; Bahl, A; Barthelemy, P; Basso, U; Beuzeboc, P; Birtle, A; Butt, M; Caffo, O; Chowdhury, S; Daugaard, G; De Giorgi, U; Delanoy, N; Deville, JL; Efstathiou, E; Eymard, JC; Fererro, JM; Fizazi, K; Fléchon, A; Gavrikova, T; Goupil, MG; Guillot, A; Hans, S; Hardy-Bessard, AC; Hasbini, A; Helissey, C; Krainer, M; Laguerre, B; Le Moulec, S; Lechevallier, É; Morales, R; Oudard, S; Priou, F; Sella, A; Spaeth, D; Thiery-Vuillemin, A; Thomson, A; Verret, B | 1 |
| Hongo, H; Kosaka, T; Oya, M | 1 |
| Hongo, H; Kosaka, T; Oya, M; Yanai, Y | 1 |
| Kazama, H; Matsubara, N; Matsuyama, H; Seto, T; Suzuki, K; Tsukube, S | 1 |
| Cuevas Sanz, JM; García García-Porrero, Á; González-Del-Alba, A; Méndez-Vidal, MJ; Muñoz Del Toro, JR; Pinto, A; Puente, J; Rodríguez, Á; Sala-Gonzalez, N; Useros Rodríguez, E; Vázquez, S | 1 |
| Babasaki, T; Goto, K; Han, X; Hayashi, T; Inoue, S; Kawaguchi, T; Matsubara, A; Sekino, Y; Shiota, M; Teishima, J; Yasui, W | 1 |
| Komai, Y; Kondo, Y; Numao, N; Ogawa, M; Yamamoto, S; Yasuoka, S; Yonese, J; Yuasa, T | 1 |
| Carbonetti, G; Clement, T; Converso, C; Kaczocha, M; Ojima, I; Trotman, LC; Wang, C | 1 |
| Balestra, A; Droz-Perroteau, C; Fizazi, K; Fourrier-Reglat, A; Guiard, E; Joly, F; Jove, J; Lacueille, C; Lamarque, S; Moore, N; Oudard, S; Rouyer, M; Tubach, F | 1 |
| Bergman, A; Bianchini, D; Bournakis, E; Bria, E; Caffo, O; De Giorgi, U; Galli, L; Gelderblom, H; Oudard, S; Pappagallo, G; Schmid, S; Sella, A; Sperduti, I; Thomsen, FB; Tucci, M; Wissing, M; Yu, EY; Zagonel, V | 1 |
| Arai, Y; Habuchi, T; Hatakeyama, S; Hoshi, S; Ishida, M; Ishidoya, S; Ito, A; Kawaguchi, T; Kawamura, S; Mitsuzuka, K; Narita, S; Ohyama, C; Okita, K; Sakurai, T; Sato, H; Shimoda, J; Takahashi, M; Tsuchiya, N | 1 |
| Chen, X; Han, W; Wan, J; Wang, H; Xie, B | 1 |
| Badrising, SK; Beeker, A; Bergman, AM; Celik, F; Coenen, JLLM; Haanen, JB; Hamberg, P; Lam, MGEH; Loosveld, OJL; Louhanepessy, RD; Oostdijk, A; van der Noort, V; Vegt, E; Wagenaar, N; Zuetenhorst, H; Zwart, W | 1 |
| Baretton, GB; Diehl, T; Erb, HHH; Haferkamp, A; Hemmerlein-Thomas, M; Jüngel, E; Neisius, A; Sommer, U; Sparwasser, P; Thomas, C; Tsaur, I | 1 |
| George, DJ; Higano, CS; Jiao, X; Kalinovský, J; Miller, K; Saad, F; Sartor, O; Sternberg, CN; Tangirala, K; Tombal, B | 1 |
| Abou Chakra, M; Dellis, A; Moussa, M; Papatsoris, A; Sryropoulou, D | 1 |
| Lü, X; Schaefer, HF; Song, C; Wang, C; Xie, Y; Zhang, C; Zhang, M; Zhu, L | 1 |
| Bai, Y; Balk, SP; Bhatt, RS; Bubley, GJ; Calagua, C; Corey, E; Giannakakou, P; Gianolio, DA; Gjyrezi, A; Khanna, P; Kung, J; Mace, S; Montgomery, B; Voznesensky, O; Wu, J; Xie, F | 1 |
| Ahmed, ME; Alamiri, J; Alom, M; Andrews, JR; Haloi, R; Higa, J; Jeffrey Karnes, R; Joshi, V; Kwon, E; Motterle, G; Shah, PH | 1 |
| Wan, Z; Wang, L; Xie, F; Zhang, G; Zhang, H | 1 |
| Iwamoto, H; Izumi, K; Kadomoto, S; Kadono, Y; Kano, H; Makino, T; Mizokami, A; Naito, R; Shigehara, K; Shimada, T; Yaegashi, H | 1 |
| de Wit, R; Freedland, S; Tombal, B | 1 |
| Hervonen, P; Huttunen, T; Jekunen, A; Kataja, V; Kautio, AL; Kellokumpu-Lehtinen, PL; Klintrup, K; Leskinen, M; Luukkaa, M; Marttila, T; Pulkkanen, K; Utriainen, T | 1 |
| Li, Q; Xie, D; Zhang, PF | 1 |
| Abouassaly, R; Bryk, DJ; Ericson, K; Fascelli, M; Haywood, SC; Khanna, A; Murthy, PB; O'Connor, LP; Yerram, NK | 1 |
| Aben, KKH; Bergman, AM; Coenen, JLLM; de Wit, R; Gerritsen, WR; Kuppen, MCP; Mehra, N; Somford, DM; Uyl-de Groot, CA; van den Bergh, ACM; van den Eertwegh, AJM; van Moorselaar, RJA; van Oort, IM; Westgeest, HM | 1 |
| Alongi, F; Alongi, P; Baldari, S; Borsatti, E; Bortolus, R; Caffo, O; Cortesi, E; Costa, RP; De Giorgi, U; De Vincentis, G; Donner, D; Facchini, G; Fanti, S; Frantellizzi, V; Galli, L; Lo Re, G; Masini, C; Monari, F; Morabito, A; Pignata, S; Pinto, C; Salgarello, M; Sbrana, A; Spada, M; Tucci, M; Zichi, C | 1 |
| Fujita, Y; Hishida, S; Iinuma, K; Ito, M; Kato, T; Kawakami, K; Koie, T; Miura, Y; Mizutani, K; Nakane, K; Takai, M; Tsuchiya, T | 1 |
| Fujiwara, M; Fujiwara, R; Komai, Y; Numao, N; Oguchi, T; Yamamoto, S; Yasuoka, S; Yonese, J; Yuasa, T | 1 |
| Glaeske, G; Horenkamp-Sonntag, D; Kreis, K; Schneider, U; Weissbach, L; Zeidler, J | 1 |
| Bamias, A; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Melichar, B; Ozatilgan, A; Poole, EM; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C | 1 |
| Kawakami, A; Matsushita, Y; Miyake, H; Sato, R; Watanabe, H; Watanabe, K | 1 |
| Chao, OS; Goodman, OB | 1 |
| Armstrong, CM; D'Abronzo, LS; Evans, CP; Gao, AC; Lombard, AP; Lou, W; Ning, S | 1 |
| Deveci Ozkan, A; Guney Eskiler, G; Kaleli, S; Sahin, E | 1 |
| Capart, P; Combest, AJ; de Wit, R; Freedland, SJ; Marinov, G; Morgans, AK; Oudard, S; Ozatilgan, A; Peterson, R | 1 |
| Anton, A; Azad, A; Chazan, G; Gibbs, P; Goh, J; Gunjur, A; Kwan, EM; Parente, P; Parnis, F; Shapiro, J; Spain, L; Torres, J; Tran, B; Weickhardt, A; Wong, S | 1 |
| Enokida, H; Hashine, K; Ichikawa, T; Kamiyama, M; Matsuyama, H; Mizokami, A; Nakajima, K; Nishimoto, K; Shiina, H; Sugiyama, Y; Takahashi, S | 1 |
| Alimohamed, N; Batuyong, E; Gagnon, R; Lee-Ying, R; Watson, AS | 1 |
| Hongo, H; Kamisawa, K; Kosaka, T; Matsumoto, K; Nakamura, K; Nishihara, H; Oya, M; Takeda, T; Yasumizu, Y | 1 |
| Drea, E; Garcia, D; Guan, AKD; Hutson, T; Morgans, AK; Vogelzang, NJ; Zhou, A | 1 |
| Egawa, S; Karakiewicz, PI; Kawada, T; Kimura, T; König, F; Laukhtina, E; Mostafaei, H; Motlagh, RS; Nyirady, P; Pallauf, M; Pradere, B; Quhal, F; Rajwa, P; Shariat, SF; Yanagisawa, T | 1 |
| Alone, M; Bhattacharjee, A; Dhumal, S; Kumar, S; Menon, N; Nawale, KP; Noronha, V; Patil, V; Prabhash, K; Waratkar, G | 1 |
| Lovell, JF; Sun, B; Zhang, Y | 1 |
| Daaka, Y; Ishov, AM; Morozov, VM; Purayil, H; Sarwar, S | 1 |
| Borgmann, H; Borkowetz, A; Dotzauer, R; Hoffmann, MA; Höfner, T; Klümper, N; Lieb, V; Linxweiler, J; Neuberger, M; von Hardenberg, J; Wenzel, M; Worst, TS | 1 |
| Ashizawa, T; Hirano, H; Horie, S; Lu, Y; Nagata, M; Nagaya, N; Nakamura, S | 1 |
| Chihara, I; Fujimoto, T; Hashimoto, K; Kamoto, T; Kawanishi, H; Kubota, M; Magaribuchi, T; Nakashima, M; Narita, S; Okabe, K; Sakurai, T; Sawada, A; Shimizu, Y; Terada, N; Tohi, Y; Uegaki, M; Yamada, Y; Yatsuda, J | 1 |
| Hakamata, Y; Imai, S; Kanda, Y; Sugiura, K; Yoneda, T | 1 |
| Cang, S; Guo, Y; Li, M; Liu, L; Xu, D; Zhang, H; Zhang, J | 1 |
| Cardoso, AM; Coelho, RS; Maia, CJ; Nascimento, D; Passarinha, LA; Rocha, SM; Socorro, S | 1 |
| Bui-Linh, C; Olivieri, M; Thornton, JM; Uba, AI; Wu, C | 1 |
| Hiratsuka, K; Iwamoto, H; Izumi, K; Kadomoto, S; Mizokami, A; Naito, R; Nakata, H; Natsagdorj, A; Shigehara, K; Yaegashi, H | 1 |
| Haldrup, J; Schmidt, L; Sørensen, KD; Weiss, S | 1 |
| Kazama, H; Matsubara, N; Matsuyama, H; Seto, T; Sunaga, Y; Suzuki, K | 1 |
| Baba, Y; Fujiwara, S; Kamisawa, K; Kosaka, T; Matsumoto, K; Nishimoto, Y; Oya, M; Takeda, T; Watanabe, K | 1 |
| Thomas, C | 1 |
69 review(s) available for docetaxel anhydrous and cabazitaxel
| Article | Year |
|---|---|
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
Topics: Animals; Biological Products; Chemistry, Pharmaceutical; Humans | 2018 |
Critical appraisal of cabazitaxel in the management of advanced prostate cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Male; Mice; Neutropenia; Prednisone; Prostatic Neoplasms; Rats; Taxoids | 2010 |
Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2010 |
New options for the management of castration-resistant prostate cancer: a case perspective.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Immunotherapy; Male; Prostatectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Treatment Outcome | 2011 |
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Forecasting; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Failure | 2011 |
[Castration resistant prostate cancer 2011].
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Tissue Extracts | 2011 |
Current clinical trials in castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Neovascularization, Pathologic; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Tissue Extracts; Treatment Outcome | 2011 |
New treatment options for castrate-resistant prostate cancer: a urology perspective.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Chemotherapy, Adjuvant; Docetaxel; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2011 |
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Radioisotopes; Taxoids; Tissue Extracts | 2011 |
[Second line therapy for castration-resistant prostate cancer (CRPC)].
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Recurrence, Local; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Survival Rate; Taxoids; Tissue Extracts | 2012 |
[Management of metastatic castration-resistant prostate cancer following docetaxel].
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms; Radioisotopes; Radium; Taxoids; Treatment Failure | 2012 |
[Strategy in advanced castration-resistant prostate cancer].
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cancer Vaccines; Denosumab; Diphosphonates; Docetaxel; Estramustine; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Zoledronic Acid | 2012 |
Castration-resistant prostate cancer: systemic therapy in 2012.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Docetaxel; Evidence-Based Medicine; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2012 |
Metastatic castrate-resistant prostate cancer: dawn of a new age of management.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms; Taxoids | 2012 |
Metastatic hormone refractory prostate cancer: recent advances in standard treatment paradigm, and future directions.
Topics: Androgen Antagonists; Androstenes; Androstenols; Angiogenesis Inhibitors; Antineoplastic Agents; Cancer Vaccines; Cathepsin K; Dendritic Cells; Docetaxel; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms; Radiopharmaceuticals; RANK Ligand; Receptors, Endothelin; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; src-Family Kinases; Taxoids; Tissue Extracts | 2014 |
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunotherapy; Male; Orchiectomy; Prostatic Neoplasms; Taxoids | 2012 |
Cabazitaxel: a novel drug for hormone-refractory prostate cancer.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Approval; Drug Resistance, Neoplasm; Humans; Male; Prostate; Prostatic Neoplasms; Taxoids; Tubulin Modulators | 2013 |
Management of advanced prostate cancer in senior adults: the new landscape.
Topics: Aged; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Castration; Clinical Trials as Topic; Disease Management; Docetaxel; Drug Resistance, Neoplasm; Humans; Life Expectancy; Male; Prostate; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2012 |
Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Docetaxel; Drug Design; Endothelin Receptor Antagonists; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Research; Taxoids; Treatment Outcome | 2012 |
Quality of life with advanced metastatic prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Denosumab; Diphosphonates; Disease Progression; Docetaxel; Health Status Indicators; Humans; Imidazoles; Male; Mitoxantrone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Outcome; Zoledronic Acid | 2012 |
Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radium; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Failure | 2012 |
Brain metastases from prostate cancer: an emerging clinical problem with implications for the future therapeutic scenario.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids | 2012 |
Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prognosis; Prostatic Neoplasms; Survival Rate; Taxoids | 2013 |
[Metastatic prostate cancer: new insights and developments].
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Denosumab; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Taxoids | 2013 |
Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tissue Extracts | 2013 |
Perspectives on treatment of metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2013 |
[The non-hormonal treatment of metastatic prostate cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Cisplatin; Denosumab; Docetaxel; Etoposide; Humans; Male; Mitoxantrone; Organometallic Compounds; Organophosphorus Compounds; Osteoporosis; Prostatic Neoplasms; Radiation Protection; Radioisotopes; Radium; RANK Ligand; Strontium; Strontium Radioisotopes; Taxoids | 2013 |
Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids | 2014 |
Evolution of the treatment paradigm for patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality Improvement; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome; United Kingdom | 2013 |
The Utility of Chemotherapy in the Treatment of Metastatic Prostate Cancer.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostate; Prostatic Neoplasms; Taxoids | 2016 |
Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
Topics: Alpha Particles; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Cancer Vaccines; Chlorides; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Taxoids; Tissue Extracts | 2013 |
Challenges in treating advanced disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Invasiveness; Neoplasm Staging; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2013 |
Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials as Topic; Docetaxel; Humans; Male; Neutropenia; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids | 2014 |
Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Taxoids; Tissue Extracts | 2014 |
Practical guide to the use of chemotherapy in castration resistant prostate cancer.
Topics: Antineoplastic Agents; Docetaxel; Drug Therapy; Drug Therapy, Combination; Humans; Male; Practice Guidelines as Topic; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Treatment Outcome | 2014 |
[Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring].
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.
Topics: Abiraterone Acetate; Androstadienes; Benzamides; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Practice Guidelines as Topic; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2014 |
Metabolism of the taxanes including nab-paclitaxel.
Topics: Albumins; Animals; Antineoplastic Agents; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Humans; Liver; Neoplasms; Paclitaxel; Taxoids | 2015 |
Corticosteroids in the management of prostate cancer: a critical review.
Topics: Adrenal Cortex Hormones; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Palliative Care; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2015 |
[How to manage patients with CRPC?].
Topics: Abiraterone Acetate; Androstenes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Tissue Extracts | 2015 |
Sequencing of agents in castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids; Tissue Extracts; Treatment Outcome | 2015 |
Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.
Topics: Abiraterone Acetate; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 Enzyme Inhibitors; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Young Adult | 2015 |
Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Topics: Androgen Antagonists; Animals; Cell Cycle Checkpoints; Docetaxel; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Humans; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Taxoids | 2015 |
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Taxoids; Tissue Extracts | 2015 |
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids | 2015 |
What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
Treatment regimens of classical and newer taxanes.
Topics: Albumins; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Liver; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome; Tubulin Modulators | 2016 |
Taxane anticancer agents: a patent perspective.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Delivery Systems; Drug Design; Female; Humans; Male; Nanostructures; Neoplasms; Paclitaxel; Patents as Topic; Taxoids | 2016 |
Recent advances in design, synthesis and bioactivity of paclitaxel-mimics.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Multiple; Humans; Mice; Molecular Structure; Neoplasms; Paclitaxel; Taxoids | 2016 |
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Dasatinib; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Taxoids; Zoledronic Acid | 2016 |
Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review.
Topics: Androgen Receptor Antagonists; Benzamides; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Platinum Compounds; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Treatment Outcome | 2016 |
Understanding the role of new systemic agents in the treatment of prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Taxoids; Tissue Extracts | 2016 |
Early use of chemotherapy in metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; History, 20th Century; History, 21st Century; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Time Factors | 2017 |
Aged patients with metastatic castration resistant prostate cancer: Should we treat with chemotherapy?
Topics: Aged; Antineoplastic Agents; Docetaxel; Geriatric Assessment; Humans; Male; Neoplasm Metastasis; Patient Selection; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Humans; Japan; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prognosis; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids | 2017 |
Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature.
Topics: Androstenes; Benzamides; Compassionate Use Trials; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2017 |
[Monitoring of treatment for metastatic castration-resistant prostate cancer].
Topics: Abiraterone Acetate; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Docetaxel; Humans; Male; Neoplastic Cells, Circulating; Nitriles; Outcome and Process Assessment, Health Care; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids | 2017 |
Dose considerations for anti-cancer drugs in metastatic prostate cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cognition Disorders; Docetaxel; Dose-Response Relationship, Drug; Fatigue; Humans; Male; Precision Medicine; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
[Metastatic prostate cancer : Update: position paper for the use of chemotherapy].
Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Docetaxel; Early Medical Intervention; Evidence-Based Medicine; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2017 |
Current approaches to incorporation of radium-223 in clinical practice.
Topics: Androstenes; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Receptors, Androgen; Taxoids; Treatment Outcome | 2018 |
The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Network Meta-Analysis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2018 |
[DNA damage repair: An emerging strategy in metastatic prostate cancer].
Topics: Androstenes; Antineoplastic Agents; Benzamides; DNA Damage; DNA Repair; Docetaxel; Genomic Instability; Humans; Male; Nitriles; Phenylthiohydantoin; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Clinical Trials as Topic; Docetaxel; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radiopharmaceuticals; Radium; Retrospective Studies; Taxoids; Thiohydantoins; Tissue Extracts | 2019 |
Pharmacotherapeutic strategies for castrate-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunotherapy; Male; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Tissue Extracts | 2020 |
Contemporary management of advanced prostate cancer: an evolving landscape.
Topics: Adenocarcinoma; Androstenes; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Diagnostic Imaging; Disease Management; Docetaxel; Humans; Male; Multicenter Studies as Topic; Nitriles; Phenylthiohydantoin; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy, Adjuvant; Radium; Taxoids; Therapies, Investigational | 2021 |
Real-World Cabazitaxel Use and Outcomes in Metastatic Castrate-Resistant Prostate Cancer: The Impact of Response to First ARPI.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2022 |
Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis.
Topics: Docetaxel; Hemoglobins; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Current development of cabazitaxel drug delivery systems.
Topics: Antineoplastic Agents; Docetaxel; Drug Delivery Systems; Humans; Male; Taxoids | 2023 |
[Role of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) treatment: still standard or exception?]
Topics: Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2023 |
26 trial(s) available for docetaxel anhydrous and cabazitaxel
| Article | Year |
|---|---|
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Neutropenia; Pain Measurement; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Failure; Treatment Outcome | 2010 |
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.
Topics: Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Pain; Pain Measurement; Palliative Care; Peripheral Nervous System Diseases; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Survival; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Docetaxel; Drug Administration Schedule; Hemoglobins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Models, Statistical; Multivariate Analysis; Nomograms; Organoplatinum Compounds; Pain; Predictive Value of Tests; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2013 |
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Spain; Taxoids | 2014 |
Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Docetaxel; Dose-Response Relationship, Drug; Humans; Japan; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biomarkers, Tumor; Blood Proteins; Cell Death; Cell Line, Tumor; Cohort Studies; Computational Biology; Docetaxel; Drug Resistance, Neoplasm; Exosomes; Extracellular Matrix; Humans; Intracellular Signaling Peptides and Proteins; Male; Nanoparticles; Poly(A)-Binding Proteins; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Proteome; Taxoids | 2015 |
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2015 |
Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Granulocyte Colony-Stimulating Factor; Humans; Kallikreins; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Male; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Neutrophils; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Severity of Illness Index; Taxoids; Time Factors; Treatment Outcome | 2016 |
TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oncogene Proteins, Fusion; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2016 |
A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Substitution; Dyspnea; Fatigue; Female; Gastrointestinal Diseases; Greece; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome | 2016 |
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2017 |
A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Etidronic Acid; Humans; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2017 |
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.
Topics: Aged; Biomarkers, Tumor; Cell Nucleus; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kallikreins; Male; Neoplastic Cells, Circulating; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids | 2017 |
No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2017 |
Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2017 |
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, ph
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Internationality; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prednisone; Prognosis; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Thionucleotides; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Canada; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Emergency Service, Hospital; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Multivariate Analysis; Nitriles; Ontario; Phenylthiohydantoin; Population Surveillance; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2018 |
Overview of Systemic Therapy Augmenting Management of High-risk Localized Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Humans; Male; Prostatic Neoplasms; Radiotherapy; Taxoids; Treatment Outcome; Tubulin Modulators | 2019 |
Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study.
Topics: Aged; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2019 |
Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Multivariate Analysis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2018 |
Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2019 |
Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel.
Topics: Aged; Androgen Receptor Antagonists; Docetaxel; Humans; Male; Molecular Targeted Therapy; Prognosis; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2020 |
Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Retreatment; Taxoids; Treatment Outcome | 2020 |
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2021 |
Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2022 |
143 other study(ies) available for docetaxel anhydrous and cabazitaxel
| Article | Year |
|---|---|
Synthesis and biological evaluation of novel cabazitaxel analogues.
Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Humans; KB Cells; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Taxoids; Xenograft Model Antitumor Assays | 2021 |
XRP6258-induced gene expression patterns in head and neck cancer carcinoma.
Topics: Annexin A5; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cyclin A; Cyclin B1; Docetaxel; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Phosphorylation; Taxoids; Tumor Cells, Cultured | 2010 |
Cabazitaxel in prostate cancer: stretching a string.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Drug Approval; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Quality of Life; Taxoids; Tissue Extracts | 2010 |
Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2011 |
Cabazitaxel: filling one of the gaps in the treatment of prostate cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Taxoids; Tubulin | 2010 |
Cabazitaxel: a new drug for metastatic prostate cancer.
Topics: Antineoplastic Agents; Docetaxel; Drug Approval; Humans; Male; Mitoxantrone; Orchiectomy; Prostatic Neoplasms; Taxoids | 2011 |
[Jevtana: clinically significant improvement in survival of patients previously treated with docetaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Glucocorticoids; Humans; Male; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Case report: responses to cabazitaxel in metastatic castration-resistant prostate cancer after extensive docetaxel treatment.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prostatic Neoplasms; Radiotherapy; Taxoids | 2011 |
New treatment options for patients with metastatic castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Zoledronic Acid | 2012 |
Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Congresses as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Male; Palliative Care; Patient-Centered Care; Prognosis; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Taxoids | 2012 |
[Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients].
Topics: Aged; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Compassionate Use Trials; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2012 |
Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Male; Neoplasm Recurrence, Local; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2012 |
NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Evidence-Based Medicine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Prostatic Neoplasms; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; United Kingdom | 2012 |
[Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Prednisolone; Prostatic Neoplasms; Taxoids | 2012 |
Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: the role of cabazitaxel in the continuum of care.
Topics: Antineoplastic Agents; Continuity of Patient Care; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2012 |
Novel and bone-targeted agents for CRPC.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Docetaxel; Humans; Ipilimumab; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tissue Extracts; Tumor Microenvironment | 2012 |
The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cytotoxins; Disease Progression; Docetaxel; Drug Therapy, Combination; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2012 |
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Compassionate Use Trials; Disease-Free Survival; Docetaxel; Fever; Germany; Humans; Kallikreins; Male; Middle Aged; Neutropenia; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thrombocytopenia; Treatment Failure; Treatment Outcome | 2013 |
ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; In Vitro Techniques; Male; Multidrug Resistance-Associated Proteins; Prostatic Neoplasms; Taxoids | 2013 |
Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, Liquid; Docetaxel; Drug Stability; Humans; Least-Squares Analysis; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Taxoids | 2013 |
Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Melanoma, Experimental; Mice; Microtubule Proteins; Neoplasms; Protein Stability; Taxoids | 2013 |
Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Docetaxel; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2013 |
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
Topics: Active Transport, Cell Nucleus; Androstenes; Androstenols; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Nucleus; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Green Fluorescent Proteins; Humans; Male; Microscopy, Confocal; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Time-Lapse Imaging | 2013 |
Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.
Topics: Abiraterone Acetate; Aged; Androstadienes; Antineoplastic Agents; Benzamides; Cohort Studies; Compassionate Use Trials; Disease-Free Survival; Docetaxel; Humans; Kallikreins; Linear Models; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Failure; Treatment Outcome | 2014 |
US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Denosumab; Diphosphonates; Docetaxel; Drug Approval; Drugs, Investigational; Estramustine; Goserelin; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Oligopeptides; Phenylthiohydantoin; Prostatic Neoplasms; Radioisotopes; Radium; Taxoids; Tissue Extracts; United States; United States Food and Drug Administration; Zoledronic Acid | 2014 |
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure | 2014 |
Introduction: why a supplement on taxanes?
Topics: Antineoplastic Agents; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 2014 |
Influence of drug formulation on OATP1B-mediated transport of paclitaxel.
Topics: Animals; Antineoplastic Agents; Biological Transport; Bridged-Ring Compounds; Cell Line; Chemistry, Pharmaceutical; CHO Cells; Cricetulus; Docetaxel; Drug Interactions; HEK293 Cells; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Mice; Mice, Inbred DBA; Mice, Knockout; Oocytes; Organic Anion Transporters; Paclitaxel; Taxoids; Tissue Distribution; Xenopus laevis | 2014 |
Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; France; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Signal Transduction; Taxoids; Time Factors; Treatment Outcome | 2015 |
Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids | 2015 |
Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Docetaxel; Drug Screening Assays, Antitumor; Female; Humans; MCF-7 Cells; Microtubules; Mitosis; Protein Stability; Taxoids; Tubulin Modulators | 2014 |
Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2014 |
Efficacy of cabazitaxel in mouse models of pediatric brain tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Disease Models, Animal; Docetaxel; Drug Evaluation, Preclinical; Female; Humans; Male; Maximum Tolerated Dose; Medulloblastoma; Mice; Mice, Inbred C57BL; Mice, Nude; Neuroectodermal Tumors; Rhabdoid Tumor; Survival Analysis; Taxoids; Teratoma; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2015 |
[18F]fluoromethylcholine as a chemotherapy response read-out in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Choline; Docetaxel; Drug Screening Assays, Antitumor; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Inhibitory Concentration 50; Male; Prostatic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Rhodamines; Taxoids | 2015 |
ERG induces taxane resistance in castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cohort Studies; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids; Trans-Activators; Transcriptional Regulator ERG; Tubulin | 2014 |
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Benzamides; Cohort Studies; Disease-Free Survival; Docetaxel; Humans; Italy; Male; Multivariate Analysis; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Failure; Treatment Outcome | 2015 |
Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
Topics: Aged; Animals; Antineoplastic Agents; Benzamides; Disease Models, Animal; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Ki-67 Antigen; Male; Mice; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2015 |
Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Cell Survival; Chromatography, Liquid; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Prostate; Prostatic Neoplasms; Tandem Mass Spectrometry; Taxoids; Y-Box-Binding Protein 1 | 2015 |
Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Flow Cytometry; Humans; Immunoblotting; Male; Mice; Microscopy, Fluorescence; Models, Molecular; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Transcriptome; Xenograft Model Antitumor Assays | 2015 |
Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel.
Topics: Alopecia; Clinical Trials as Topic; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Dysgeusia; Humans; Male; Nail Diseases; Peripheral Nervous System Diseases; Prospective Studies; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2015 |
Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Exosomes; Humans; Male; Prostatic Neoplasms, Castration-Resistant; RNA, Small Interfering; Taxoids; Transfection | 2015 |
Elucidating the mechanism of action of the clinically approved taxanes: a comprehensive comparison of local and allosteric effects.
Topics: Allosteric Site; Docetaxel; Humans; Microtubules; Molecular Docking Simulation; Molecular Dynamics Simulation; Paclitaxel; Protein Multimerization; Protein Structure, Secondary; Taxoids; Tubulin; Tubulin Modulators | 2015 |
Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.
Topics: Aged; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Endpoint Determination; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Failure | 2015 |
Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Docetaxel; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Treatment Outcome | 2015 |
Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Neoplasm Proteins; Neoplasms, Experimental; Taxoids; Tubulin Modulators; Xenograft Model Antitumor Assays | 2015 |
Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.
Topics: Active Transport, Cell Nucleus; Alternative Splicing; Animals; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Cytoplasm; Docetaxel; Drug Resistance, Neoplasm; Fluorescence Recovery After Photobleaching; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Ligands; Male; Microtubules; Prostatic Neoplasms, Castration-Resistant; Protein Structure, Tertiary; Receptors, Androgen; Signal Transduction; Taxoids; Transcription, Genetic; Up-Regulation | 2015 |
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Topics: Academic Medical Centers; Adenocarcinoma; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Baltimore; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Genetic Predisposition to Disease; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Cells, Circulating; Nitriles; Patient Selection; Phenotype; Phenylthiohydantoin; Predictive Value of Tests; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Risk Factors; RNA, Messenger; Taxoids; Time Factors; Treatment Outcome | 2015 |
[Chemotherapy of prostate cancer].
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Drug Therapy; Evidence-Based Medicine; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2015 |
Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer.
Topics: Androstenes; Androstenols; Benzamides; Bridged-Ring Compounds; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Taxoids | 2015 |
Role of DNA Methylation in Cabazitaxel Resistance in Prostate Cancer.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cell Survival; DNA Methylation; DNA Modification Methylases; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms; Taxoids; Time Factors | 2016 |
Translating Clinical Evidence-Based Medicine into the Real World: Single-Center Experience with Cabazitaxel in Metastatic Prostate Cancer Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Evidence-Based Medicine; Humans; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2016 |
Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Cancer Vaccines; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Singapore; Taxoids; Tissue Extracts | 2015 |
[Role of chemotherapy in the treatment of castration resistant prostate cancer].
Topics: Antinematodal Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Recurrence; Taxoids | 2016 |
Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.
Topics: Animals; Antineoplastic Agents; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Xenograft Model Antitumor Assays | 2016 |
Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Taxoids | 2016 |
Cabazitaxel for metastatic hormone-relapsed prostate cancer treated with docetaxel.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids | 2016 |
Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications?
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Loss of SLCO1B3 drives taxane resistance in prostate cancer.
Topics: Adenocarcinoma; Androgens; Androstenes; Animals; Antineoplastic Agents, Phytogenic; Benzamides; Biological Transport; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heterografts; Humans; Male; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Organic Anion Transporters, Sodium-Independent; Phenylthiohydantoin; Prostatic Neoplasms; RNA Interference; RNA, Small Interfering; Solute Carrier Organic Anion Transporter Family Member 1B3; Taxoids | 2016 |
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
Topics: Abdominal Neoplasms; Abiraterone Acetate; Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retreatment; Retrospective Studies; Survival Rate; Taxoids | 2016 |
[ASCO 2016: Confirmation of respective roles of docetaxel and cabazitaxel in prostate cancer patients].
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
Molecular complexity of taxane-induced cytotoxicity in prostate cancer cells.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Prostatic Neoplasms; Protein Translocation Systems; Proto-Oncogene Proteins p21(ras); raf Kinases; Receptors, Androgen; Taxoids; Xenograft Model Antitumor Assays | 2017 |
Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study.
Topics: Aged; Antineoplastic Agents; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Cytotoxic Effects of the Therapeutic Radionuclide Rhenium-188 Combined with Taxanes in Human Prostate Carcinoma Cell Lines.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Chemotherapy, Adjuvant; DNA Repair; Docetaxel; Dose-Response Relationship, Drug; Etidronic Acid; Humans; Male; Organometallic Compounds; Prostatic Neoplasms; Radiation-Sensitizing Agents; Radiopharmaceuticals; Taxoids | 2017 |
Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer.
Topics: Antineoplastic Agents, Phytogenic; Budgets; Computer Simulation; Cost Savings; Docetaxel; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Health Care Costs; Humans; Male; Managed Care Programs; Models, Economic; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate.
Topics: Abiraterone Acetate; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Pharmacogenetics; Prostate; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Brain; Breast Neoplasms; Cattle; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MCF-7 Cells; Microtubules; RNA, Small Interfering; Taxoids; Tubulin; Tubulin Modulators | 2017 |
ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.
Topics: Androgen Antagonists; ATP Binding Cassette Transporter, Subfamily B; Bridged-Ring Compounds; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms; Receptors, Androgen; Taxoids | 2017 |
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey.
Topics: Androstenes; Biomarkers, Tumor; Clinical Decision-Making; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Practice Patterns, Physicians'; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Surveys and Questionnaires; Taxoids; Treatment Outcome; Tubulin Modulators | 2018 |
Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Longitudinal Studies; Male; Middle Aged; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Taxoids; Treatment Outcome | 2017 |
The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer.
Topics: Biomarkers; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Management of Castration-Resistant, Taxane-Resistant Prostate Cancer.
Topics: Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Carboxymethylcellulose Sodium; Cell Line, Tumor; Delayed-Action Preparations; Docetaxel; Drug Carriers; Drug Compounding; Drug Liberation; Drug Resistance, Neoplasm; Humans; Male; Maximum Tolerated Dose; Mice, Inbred NOD; Mice, SCID; Nanoparticles; Neutropenia; Particle Size; Prostatic Neoplasms, Castration-Resistant; Solubility; Taxoids; Tissue Distribution; Xenograft Model Antitumor Assays | 2017 |
[Metastatic castration-resistant prostate cancer : Use of cabazitaxel taking into consideration current data].
Topics: Docetaxel; Humans; Male; Neoplasms, Second Primary; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
[Experience with cabazitaxel therapy for patients with metastatic castrate resistant prostate cancer in Hungary].
Topics: Age Factors; Aged; Biopsy, Needle; Cohort Studies; Disease-Free Survival; Docetaxel; Humans; Hungary; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Patient Safety; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2018 |
Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Docetaxel; Humans; Male; Meta-Analysis as Topic; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Salvage Therapy; Survival Rate; Taxoids | 2018 |
Re: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
Topics: Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Eye Proteins; Humans; Macrophages; Male; Mice; Mice, SCID; Neoplasm Metastasis; Nerve Growth Factors; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; Recombinant Proteins; Serpins; Taxoids; Xenograft Model Antitumor Assays | 2018 |
MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.
Topics: Biomimetic Materials; Cell Line, Tumor; Cell Survival; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Male; MicroRNAs; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Patient Selection; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2018 |
Application of Mixture Design Response Surface Methodology for Combination Chemotherapy in PC-3 Human Prostate Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dioxolanes; Docetaxel; Drug Synergism; Flavonoids; Humans; Male; Mitoxantrone; Models, Statistical; Piperidines; Prostatic Neoplasms; Resveratrol; Taxoids | 2018 |
Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Prostatic Neoplasms; Receptors, Androgen; Taxoids | 2018 |
UV spectroscopy and least square matching for high throughput discrimination of taxanes in commercial formulations and compounded bags.
Topics: Calibration; Docetaxel; Drug Compounding; Least-Squares Analysis; Paclitaxel; Spectrophotometry, Ultraviolet; Taxoids | 2018 |
An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Neutrophils; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Survival Rate; Taxoids | 2019 |
Tritiation of azido-labeled diiodo cabazitaxel (Jevtana) and docetaxel (Taxotere) derivatives to generate
Topics: Azides; Docetaxel; Iodine; Isotope Labeling; Models, Molecular; Molecular Conformation; Photoaffinity Labels; Taxoids; Tritium | 2018 |
Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Orchiectomy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Survival Rate; Taxoids | 2018 |
Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncolo
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2018 |
Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Animals; Antineoplastic Agents; Cyclobutanes; Disease Progression; Docetaxel; Down-Regulation; Humans; Male; Mice; Neoplasm Recurrence, Local; Organoplatinum Compounds; Prostate; Prostatic Neoplasms; Receptors, Androgen; Taxoids; Transcriptional Regulator ERG | 2018 |
No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2018 |
[Chemotherapy in metastatic castration resistant prostate cancer.]
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
Lack of combination effects of soy isoflavones and taxane chemotherapy of castration-resistant prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Dietary Supplements; Docetaxel; Drug Synergism; Equol; Food-Drug Interactions; Genistein; Glycine max; Isoflavones; Male; Mice; Mice, Nude; Prostatic Neoplasms, Castration-Resistant; Random Allocation; Taxoids; Xenograft Model Antitumor Assays | 2019 |
Suppression of Taxanes Cytotoxicity by Citrus Flavonoid Hesperetin in PPC-1 Human Prostate Cancer Cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Dietary Supplements; Docetaxel; Drug Antagonism; Hesperidin; Humans; Male; Prostatic Neoplasms; Taxoids | 2018 |
Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer.
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Neoplasm Grading; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Testosterone | 2019 |
Therapeutic Effect of Cabazitaxel and Blood-Brain Barrier opening in a Patient-Derived Glioblastoma Model.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Docetaxel; Female; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasms, Experimental; Taxoids; Xenograft Model Antitumor Assays | 2019 |
Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
Topics: Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Early Detection of Cancer; Humans; Liquid Biopsy; Lung Neoplasms; Male; Neoplastic Cells, Circulating; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2019 |
Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report.
Topics: Administration, Intravenous; Aged; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Dyspnea; Follow-Up Studies; Glucocorticoids; Humans; Lung Diseases, Interstitial; Male; Methylprednisolone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Granulocyte Colony-Stimulating Factor; Humans; Kallikreins; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Safety; Taxoids; Treatment Outcome | 2019 |
Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
Topics: Abiraterone Acetate; Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Docetaxel; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Middle Aged; Multivariate Analysis; Pain; Prednisone; Progression-Free Survival; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Spain; Taxoids; Treatment Outcome | 2019 |
TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromones; Docetaxel; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Knockdown Techniques; Humans; Male; Morpholines; Prostatic Neoplasms; Protein Binding; PTEN Phosphohydrolase; Taxoids; Tubulin | 2019 |
Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Japan; Male; Middle Aged; Neoplasms, Second Primary; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Taxoids; Treatment Outcome | 2019 |
Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Drug Synergism; Fatty Acid-Binding Proteins; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; Taxoids; Xenograft Model Antitumor Assays | 2020 |
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2019 |
Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Age Factors; Aged; Androgen Receptor Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Neoplasm Grading; Nitriles; Observational Studies as Topic; Phenylthiohydantoin; Progression-Free Survival; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2020 |
The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study.
Topics: Abiraterone Acetate; Aged; Androgen Receptor Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Follow-Up Studies; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2020 |
Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Prodrugs; Rats; Rats, Sprague-Dawley; Taxoids; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2020 |
A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium; Registries; Taxoids | 2020 |
AR-V7 Protein Expression in Circulating Tumour Cells Is Not Predictive of Treatment Response in mCRPC.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Humans; Male; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2020 |
Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Follow-Up Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Tissue Extracts | 2020 |
Binding modes of cabazitaxel with the different human β-tubulin isotypes: DFT and MD studies.
Topics: Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Microtubules; Molecular Docking Simulation; Molecular Dynamics Simulation; Paclitaxel; Taxoids; Thermodynamics; Tubulin; Tubulin Modulators | 2020 |
Taxane resistance in prostate cancer is mediated by decreased drug-target engagement.
Topics: Animals; Bridged-Ring Compounds; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mice; Mice, Nude; Microtubules; Prostatic Neoplasms; Taxoids | 2020 |
Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure | 2020 |
Preparation and Evaluation of Cabazitaxel-Loaded Bovine Serum Albumin Nanoparticles for Prostate Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chromatography, Liquid; Contrast Media; Docetaxel; Drug Carriers; Humans; Magnetic Resonance Imaging; Male; Mice, Inbred BALB C; Nanoparticles; Prostatic Neoplasms; Rats, Sprague-Dawley; Serum Albumin, Bovine; Tandem Mass Spectrometry; Taxoids; Tissue Distribution | 2020 |
Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Docetaxel; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Risk Factors; Signal Transduction; Taxoids | 2021 |
Use of Chemotherapy and Androgen Signaling-targeted Inhibitors in Patients with Metastatic Prostate Cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2021 |
Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Docetaxel; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality-Adjusted Life Years; Survival Rate; Taxoids | 2021 |
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemoradiotherapy; Docetaxel; Follow-Up Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Rate; Taxoids | 2021 |
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Retrospective Studies; Survival Rate; Taxoids | 2021 |
Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Discovery; Drug Resistance, Neoplasm; Extracellular Vesicles; Humans; Male; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Proteomics; Signal Transduction; Taxoids | 2021 |
Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Docetaxel; Humans; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2021 |
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2022 |
Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
Topics: Animals; Antineoplastic Agents; Chromones; Docetaxel; Drug Resistance, Neoplasm; Humans; Ki-67 Antigen; Male; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 1; Morpholines; PC-3 Cells; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Taxoids; Xenograft Model Antitumor Assays | 2021 |
DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chromones; DNA Damage; DNA-Activated Protein Kinase; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Humans; Male; Morpholines; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridazines; Quinazolines; Taxoids | 2021 |
Activation of the
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Biomarkers, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tumor Cells, Cultured | 2021 |
Immunotherapeutic role of cabazitaxel treatment in the activation of TLR3 signalling in metastatic castration-resistant prostate cancer in vitro.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Humans; Immunotherapy; Interferon Regulatory Factor-3; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Signal Transduction; Taxoids; Toll-Like Receptor 3; Tumor Microenvironment | 2022 |
Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Docetaxel; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice.
Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Antineoplastic Agents; Bone Neoplasms; Databases, Factual; Docetaxel; Humans; Japan; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Recurrence; Taxoids; Time Factors; Treatment Outcome | 2022 |
Influence of response to prior docetaxel on sensitivity to cabazitaxel in prostate cancer patients with PTEN alterations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; PTEN Phosphohydrolase; Retrospective Studies; Taxoids; Treatment Outcome | 2022 |
An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome; United States | 2022 |
Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer.
Topics: Androgens; Bridged-Ring Compounds; Cell Cycle Proteins; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Androgen; Taxoids | 2022 |
Efficacy of cabazitaxel in fourth or later line of therapy in metastatic castration-resistant prostate cancer: Multi-institutional real-world experience in Germany.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer.
Topics: Androgens; Docetaxel; Humans; Male; Neoplastic Cells, Circulating; Nitriles; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Tomography, X-Ray Computed | 2022 |
The efficacy of sequential therapy with docetaxel and cabazitaxel for castration-resistant prostate cancer: A retrospective multi-institutional study in Japan.
Topics: Docetaxel; Humans; Japan; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
[LONG TERM ADMINISTRATION OF RELATIVE DOSE INTENSITY-ADJUSTED CABAZITAXEL FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A CASE REPORT].
Topics: Aged; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2022 |
KIF14 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer by promoting AKT phosphorylation.
Topics: Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Kinesins; Male; Oncogene Proteins; Phosphorylation; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt | 2023 |
STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Humans; Male; Oxidoreductases; Paclitaxel; Prostate; Prostatic Neoplasms; Taxoids | 2023 |
Computational analysis of drug resistance of taxanes bound to human β-tubulin mutant (D26E).
Topics: Animals; Docetaxel; Drug Resistance, Neoplasm; Humans; Paclitaxel; Swine; Taxoids; Tubulin | 2023 |
The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells.
Topics: Cell Line, Tumor; Chemokine CCL2; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Receptors, CCR2; RNA, Small Interfering | 2023 |
Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; CRISPR-Cas Systems; Docetaxel; Early Detection of Cancer; GTPase-Activating Proteins; Humans; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan.
Topics: Docetaxel; Humans; Japan; Male; Product Surveillance, Postmarketing; Prostatic Neoplasms, Castration-Resistant | 2023 |
Prognostic significance of serum testosterone level in patients with castration-resistant prostate cancer treated with cabazitaxel.
Topics: Docetaxel; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Testosterone; Treatment Outcome | 2024 |